| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 34 | 2024 | 205 | 8.550 |
Why?
|
| Body Composition | 32 | 2024 | 153 | 4.430 |
Why?
|
| Obesity | 31 | 2025 | 367 | 4.200 |
Why?
|
| Bone Density | 30 | 2025 | 107 | 4.180 |
Why?
|
| Adiposity | 18 | 2022 | 96 | 3.790 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2025 | 139 | 3.570 |
Why?
|
| Hypertension | 17 | 2024 | 419 | 3.410 |
Why?
|
| Female | 133 | 2025 | 9103 | 3.190 |
Why?
|
| Humans | 157 | 2025 | 14537 | 2.950 |
Why?
|
| Body Mass Index | 36 | 2025 | 321 | 2.780 |
Why?
|
| Male | 87 | 2025 | 6754 | 2.520 |
Why?
|
| South Africa | 100 | 2025 | 7596 | 2.470 |
Why?
|
| Adult | 86 | 2025 | 5913 | 2.450 |
Why?
|
| Cross-Sectional Studies | 50 | 2025 | 1422 | 2.310 |
Why?
|
| Middle Aged | 63 | 2025 | 3601 | 2.100 |
Why?
|
| Obesity, Abdominal | 7 | 2019 | 19 | 2.080 |
Why?
|
| Diabetes Mellitus | 7 | 2024 | 146 | 1.940 |
Why?
|
| Absorptiometry, Photon | 25 | 2022 | 85 | 1.810 |
Why?
|
| Risk Factors | 38 | 2025 | 1475 | 1.750 |
Why?
|
| Health Behavior | 8 | 2024 | 79 | 1.730 |
Why?
|
| Insulin Resistance | 11 | 2022 | 79 | 1.610 |
Why?
|
| Adolescent | 49 | 2024 | 2985 | 1.490 |
Why?
|
| Urban Population | 15 | 2025 | 257 | 1.430 |
Why?
|
| Prevalence | 26 | 2025 | 1192 | 1.410 |
Why?
|
| HIV Infections | 22 | 2025 | 5097 | 1.380 |
Why?
|
| Adipose Tissue | 10 | 2021 | 52 | 1.370 |
Why?
|
| Motor Activity | 10 | 2017 | 46 | 1.370 |
Why?
|
| Bone and Bones | 6 | 2022 | 38 | 1.330 |
Why?
|
| Life Style | 9 | 2025 | 86 | 1.280 |
Why?
|
| Diet | 12 | 2024 | 109 | 1.220 |
Why?
|
| Cardiovascular Diseases | 11 | 2024 | 237 | 1.210 |
Why?
|
| Dyslipidemias | 3 | 2025 | 57 | 1.140 |
Why?
|
| Young Adult | 35 | 2021 | 2498 | 1.120 |
Why?
|
| Child | 32 | 2024 | 2242 | 1.100 |
Why?
|
| Infant Behavior | 2 | 2018 | 5 | 1.100 |
Why?
|
| Metabolic Syndrome | 5 | 2024 | 64 | 1.060 |
Why?
|
| Socioeconomic Factors | 9 | 2021 | 411 | 0.970 |
Why?
|
| Running | 4 | 2017 | 6 | 0.970 |
Why?
|
| Surveys and Questionnaires | 15 | 2024 | 563 | 0.960 |
Why?
|
| Sleep | 3 | 2021 | 36 | 0.940 |
Why?
|
| Intra-Abdominal Fat | 4 | 2019 | 15 | 0.930 |
Why?
|
| Waist Circumference | 8 | 2025 | 60 | 0.920 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2025 | 61 | 0.920 |
Why?
|
| Nutritional Status | 6 | 2021 | 76 | 0.920 |
Why?
|
| Overweight | 6 | 2024 | 87 | 0.900 |
Why?
|
| Sex Factors | 10 | 2023 | 227 | 0.900 |
Why?
|
| Social Class | 4 | 2018 | 73 | 0.880 |
Why?
|
| Longitudinal Studies | 18 | 2025 | 435 | 0.870 |
Why?
|
| Anthropometry | 11 | 2020 | 102 | 0.860 |
Why?
|
| Blood Pressure | 13 | 2024 | 317 | 0.810 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 262 | 0.800 |
Why?
|
| Fractures, Bone | 6 | 2024 | 21 | 0.800 |
Why?
|
| Insulins | 1 | 2022 | 3 | 0.770 |
Why?
|
| Healthy Aging | 1 | 2022 | 6 | 0.770 |
Why?
|
| Environment | 3 | 2013 | 22 | 0.770 |
Why?
|
| Self Report | 3 | 2020 | 114 | 0.750 |
Why?
|
| Lumbar Vertebrae | 8 | 2023 | 18 | 0.730 |
Why?
|
| Walking | 4 | 2019 | 14 | 0.730 |
Why?
|
| Weight Gain | 6 | 2018 | 77 | 0.730 |
Why?
|
| Adolescent Behavior | 5 | 2024 | 60 | 0.730 |
Why?
|
| Premenopause | 8 | 2024 | 14 | 0.730 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 131 | 0.720 |
Why?
|
| Guideline Adherence | 2 | 2019 | 43 | 0.720 |
Why?
|
| Growth Disorders | 3 | 2020 | 56 | 0.710 |
Why?
|
| Genome-Wide Association Study | 4 | 2024 | 106 | 0.710 |
Why?
|
| Body Fat Distribution | 6 | 2019 | 16 | 0.710 |
Why?
|
| Africa South of the Sahara | 13 | 2025 | 353 | 0.690 |
Why?
|
| Mothers | 4 | 2019 | 195 | 0.680 |
Why?
|
| Metabolic Diseases | 3 | 2018 | 30 | 0.680 |
Why?
|
| Cohort Studies | 15 | 2024 | 967 | 0.680 |
Why?
|
| Bone Diseases, Metabolic | 4 | 2023 | 11 | 0.670 |
Why?
|
| Rural Population | 11 | 2025 | 654 | 0.670 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2024 | 6 | 0.660 |
Why?
|
| Atherosclerosis | 4 | 2022 | 100 | 0.660 |
Why?
|
| Infant | 13 | 2023 | 2244 | 0.660 |
Why?
|
| Pregnant Women | 3 | 2017 | 89 | 0.650 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 40 | 0.650 |
Why?
|
| School Health Services | 2 | 2019 | 19 | 0.640 |
Why?
|
| Carotid Intima-Media Thickness | 6 | 2023 | 108 | 0.630 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 2017 | 17 | 0.630 |
Why?
|
| Radius | 6 | 2025 | 9 | 0.620 |
Why?
|
| Athletes | 3 | 2016 | 20 | 0.620 |
Why?
|
| Bone Development | 5 | 2024 | 19 | 0.620 |
Why?
|
| Mother-Child Relations | 2 | 2019 | 20 | 0.610 |
Why?
|
| Osteoporosis | 3 | 2024 | 14 | 0.610 |
Why?
|
| Aging | 2 | 2019 | 109 | 0.600 |
Why?
|
| Aged | 18 | 2021 | 1740 | 0.600 |
Why?
|
| Models, Theoretical | 2 | 2019 | 80 | 0.580 |
Why?
|
| Fetal Development | 1 | 2018 | 19 | 0.580 |
Why?
|
| Cities | 3 | 2024 | 37 | 0.580 |
Why?
|
| Urban Health | 4 | 2024 | 78 | 0.580 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 31 | 0.570 |
Why?
|
| Child Behavior | 1 | 2017 | 11 | 0.560 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 117 | 0.560 |
Why?
|
| Body Image | 5 | 2024 | 17 | 0.550 |
Why?
|
| Vitamin D Deficiency | 3 | 2024 | 27 | 0.550 |
Why?
|
| Sports | 4 | 2019 | 43 | 0.540 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2017 | 6 | 0.540 |
Why?
|
| Premature Birth | 1 | 2018 | 80 | 0.540 |
Why?
|
| Tibia | 6 | 2025 | 14 | 0.540 |
Why?
|
| Recreation | 1 | 2017 | 4 | 0.530 |
Why?
|
| Femur | 4 | 2017 | 11 | 0.530 |
Why?
|
| Child, Preschool | 11 | 2022 | 1748 | 0.530 |
Why?
|
| Puberty | 4 | 2016 | 22 | 0.530 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2017 | 13 | 0.520 |
Why?
|
| Alcohol Drinking | 4 | 2021 | 55 | 0.520 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 3 | 0.520 |
Why?
|
| Malnutrition | 1 | 2017 | 56 | 0.510 |
Why?
|
| Pediatric Obesity | 4 | 2019 | 41 | 0.500 |
Why?
|
| Pregnancy | 9 | 2018 | 1862 | 0.490 |
Why?
|
| Body Weight | 8 | 2024 | 111 | 0.480 |
Why?
|
| Child Nutritional Physiological Phenomena | 2 | 2015 | 19 | 0.480 |
Why?
|
| Sarcopenia | 3 | 2021 | 7 | 0.480 |
Why?
|
| Africa | 9 | 2025 | 376 | 0.450 |
Why?
|
| Adipokines | 1 | 2014 | 11 | 0.450 |
Why?
|
| Sex Characteristics | 5 | 2021 | 43 | 0.440 |
Why?
|
| Femur Neck | 3 | 2016 | 8 | 0.440 |
Why?
|
| Regression Analysis | 6 | 2019 | 133 | 0.440 |
Why?
|
| Smoking | 5 | 2021 | 100 | 0.440 |
Why?
|
| Metacarpal Bones | 3 | 2018 | 9 | 0.440 |
Why?
|
| Prospective Studies | 7 | 2023 | 1160 | 0.430 |
Why?
|
| Cytokines | 1 | 2014 | 107 | 0.430 |
Why?
|
| Follow-Up Studies | 10 | 2022 | 370 | 0.420 |
Why?
|
| Menstruation Disturbances | 2 | 2007 | 7 | 0.420 |
Why?
|
| Osteoporotic Fractures | 2 | 2024 | 7 | 0.410 |
Why?
|
| Risk Assessment | 5 | 2019 | 225 | 0.390 |
Why?
|
| Health Promotion | 4 | 2019 | 109 | 0.390 |
Why?
|
| Ultrasonography | 6 | 2021 | 77 | 0.390 |
Why?
|
| Infant, Newborn | 8 | 2023 | 1479 | 0.380 |
Why?
|
| Accelerometry | 3 | 2022 | 19 | 0.370 |
Why?
|
| Blood Glucose | 9 | 2024 | 107 | 0.330 |
Why?
|
| Calcaneus | 3 | 2007 | 14 | 0.320 |
Why?
|
| Weight-Bearing | 4 | 2018 | 6 | 0.310 |
Why?
|
| Developing Countries | 4 | 2023 | 400 | 0.310 |
Why?
|
| Postmenopause | 3 | 2024 | 11 | 0.310 |
Why?
|
| Feeding Behavior | 3 | 2021 | 60 | 0.310 |
Why?
|
| Feeding and Eating Disorders | 2 | 2014 | 4 | 0.300 |
Why?
|
| Kenya | 5 | 2023 | 183 | 0.300 |
Why?
|
| Muscle, Skeletal | 4 | 2015 | 14 | 0.300 |
Why?
|
| Age Factors | 6 | 2019 | 370 | 0.300 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 468 | 0.300 |
Why?
|
| Glucose | 3 | 2024 | 45 | 0.300 |
Why?
|
| Radiography | 6 | 2023 | 80 | 0.290 |
Why?
|
| Health Status | 3 | 2021 | 111 | 0.290 |
Why?
|
| Eating | 3 | 2021 | 16 | 0.280 |
Why?
|
| Body Height | 4 | 2023 | 52 | 0.280 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2018 | 30 | 0.280 |
Why?
|
| Noncommunicable Diseases | 2 | 2020 | 77 | 0.280 |
Why?
|
| Menarche | 2 | 2023 | 13 | 0.270 |
Why?
|
| Fractures, Stress | 1 | 2007 | 2 | 0.270 |
Why?
|
| Menopause | 2 | 2024 | 24 | 0.270 |
Why?
|
| Biomarkers | 4 | 2022 | 327 | 0.260 |
Why?
|
| Phenotype | 2 | 2025 | 158 | 0.260 |
Why?
|
| Zimbabwe | 5 | 2025 | 120 | 0.260 |
Why?
|
| Health Status Disparities | 2 | 2019 | 35 | 0.260 |
Why?
|
| Comorbidity | 2 | 2019 | 188 | 0.260 |
Why?
|
| Adolescent Development | 2 | 2017 | 13 | 0.260 |
Why?
|
| Food Supply | 3 | 2021 | 29 | 0.250 |
Why?
|
| Metacarpus | 1 | 2006 | 2 | 0.250 |
Why?
|
| Lipids | 5 | 2024 | 81 | 0.250 |
Why?
|
| HIV | 5 | 2023 | 380 | 0.250 |
Why?
|
| Multimorbidity | 2 | 2023 | 42 | 0.250 |
Why?
|
| Women's Health | 2 | 2016 | 41 | 0.240 |
Why?
|
| Organ Size | 4 | 2024 | 34 | 0.240 |
Why?
|
| Cancellous Bone | 1 | 2025 | 1 | 0.240 |
Why?
|
| Physical Fitness | 2 | 2015 | 10 | 0.240 |
Why?
|
| Self Concept | 2 | 2016 | 13 | 0.230 |
Why?
|
| Rural Health | 2 | 2017 | 118 | 0.230 |
Why?
|
| Metagenome | 1 | 2025 | 6 | 0.230 |
Why?
|
| Incidence | 5 | 2025 | 685 | 0.230 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2025 | 21 | 0.230 |
Why?
|
| Ghana | 5 | 2025 | 67 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 176 | 0.230 |
Why?
|
| Birth Weight | 5 | 2023 | 80 | 0.230 |
Why?
|
| Age Determination by Skeleton | 1 | 2024 | 4 | 0.220 |
Why?
|
| Time Factors | 4 | 2019 | 507 | 0.220 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 9 | 0.220 |
Why?
|
| Cholestanes | 1 | 2024 | 2 | 0.220 |
Why?
|
| Microcirculation | 2 | 2014 | 5 | 0.220 |
Why?
|
| Child Development | 4 | 2023 | 93 | 0.220 |
Why?
|
| Qualitative Research | 2 | 2016 | 321 | 0.210 |
Why?
|
| Case-Control Studies | 4 | 2024 | 480 | 0.210 |
Why?
|
| Resistance Training | 2 | 2014 | 5 | 0.210 |
Why?
|
| Vitamin D | 3 | 2024 | 41 | 0.210 |
Why?
|
| Insulin | 6 | 2022 | 73 | 0.210 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 43 | 0.210 |
Why?
|
| Body Size | 4 | 2015 | 15 | 0.210 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 41 | 0.210 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2023 | 3 | 0.200 |
Why?
|
| Gene-Environment Interaction | 2 | 2024 | 12 | 0.200 |
Why?
|
| Glucose Intolerance | 2 | 2019 | 5 | 0.190 |
Why?
|
| Travel-Related Illness | 1 | 2021 | 3 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 3 | 2016 | 551 | 0.190 |
Why?
|
| Travel | 1 | 2021 | 21 | 0.180 |
Why?
|
| Personal Satisfaction | 3 | 2016 | 16 | 0.180 |
Why?
|
| Tobacco | 1 | 2021 | 14 | 0.180 |
Why?
|
| Urbanization | 1 | 2020 | 11 | 0.170 |
Why?
|
| Geography | 2 | 2018 | 60 | 0.170 |
Why?
|
| Sex Distribution | 2 | 2018 | 89 | 0.170 |
Why?
|
| Hyperinsulinism | 1 | 2020 | 4 | 0.170 |
Why?
|
| Triglycerides | 2 | 2025 | 47 | 0.170 |
Why?
|
| Exercise Therapy | 1 | 2020 | 14 | 0.170 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 101 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 18 | 0.160 |
Why?
|
| Faith-Based Organizations | 1 | 2019 | 1 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 9 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 50 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.160 |
Why?
|
| Kidney Diseases | 1 | 2019 | 38 | 0.160 |
Why?
|
| Cross-Cultural Comparison | 2 | 2016 | 16 | 0.160 |
Why?
|
| Global Health | 1 | 2020 | 193 | 0.160 |
Why?
|
| Bile Acids and Salts | 1 | 2019 | 3 | 0.160 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2019 | 4 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
| Phospholipids | 1 | 2019 | 13 | 0.150 |
Why?
|
| Luteinizing Hormone | 1 | 2019 | 5 | 0.150 |
Why?
|
| Leisure Activities | 2 | 2019 | 9 | 0.150 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2019 | 11 | 0.150 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2019 | 7 | 0.150 |
Why?
|
| Testosterone | 1 | 2019 | 14 | 0.150 |
Why?
|
| Estradiol | 1 | 2019 | 18 | 0.150 |
Why?
|
| Frailty | 1 | 2019 | 15 | 0.150 |
Why?
|
| Social Support | 2 | 2016 | 77 | 0.150 |
Why?
|
| Inflammation | 1 | 2019 | 104 | 0.150 |
Why?
|
| Hand Strength | 3 | 2021 | 7 | 0.150 |
Why?
|
| Linear Models | 2 | 2019 | 83 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 198 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 20 | 0.140 |
Why?
|
| Acetylcholine | 2 | 2014 | 3 | 0.140 |
Why?
|
| Physical Conditioning, Human | 1 | 2017 | 2 | 0.140 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 9 | 0.140 |
Why?
|
| Endothelium, Vascular | 2 | 2014 | 29 | 0.130 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2017 | 8 | 0.130 |
Why?
|
| Genomics | 1 | 2018 | 109 | 0.130 |
Why?
|
| Awareness | 1 | 2017 | 18 | 0.130 |
Why?
|
| Family Characteristics | 1 | 2017 | 135 | 0.130 |
Why?
|
| Research Report | 1 | 2016 | 11 | 0.130 |
Why?
|
| Hemiplegia | 1 | 2016 | 1 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 217 | 0.130 |
Why?
|
| Cholesterol, LDL | 3 | 2025 | 150 | 0.130 |
Why?
|
| Physical Endurance | 1 | 2016 | 3 | 0.130 |
Why?
|
| Cerebral Palsy | 1 | 2016 | 12 | 0.130 |
Why?
|
| Independent Living | 1 | 2016 | 6 | 0.130 |
Why?
|
| Burkina Faso | 3 | 2021 | 29 | 0.130 |
Why?
|
| Attitude | 1 | 2016 | 12 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2018 | 325 | 0.120 |
Why?
|
| Diabetes, Gestational | 1 | 2016 | 38 | 0.120 |
Why?
|
| Cortical Bone | 1 | 2015 | 1 | 0.120 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2015 | 5 | 0.120 |
Why?
|
| Health Policy | 3 | 2024 | 140 | 0.120 |
Why?
|
| Models, Biological | 1 | 2015 | 77 | 0.120 |
Why?
|
| Benzoxazines | 1 | 2015 | 123 | 0.120 |
Why?
|
| Muscle Development | 1 | 2015 | 2 | 0.120 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 118 | 0.120 |
Why?
|
| Demography | 2 | 2015 | 105 | 0.120 |
Why?
|
| Economic Development | 1 | 2014 | 5 | 0.110 |
Why?
|
| Child Nutrition Disorders | 1 | 2014 | 13 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2014 | 12 | 0.110 |
Why?
|
| Weight Loss | 1 | 2014 | 12 | 0.110 |
Why?
|
| Focus Groups | 1 | 2015 | 196 | 0.110 |
Why?
|
| Motorcycles | 1 | 2014 | 1 | 0.110 |
Why?
|
| Energy Intake | 3 | 2021 | 24 | 0.110 |
Why?
|
| Muscle Strength | 1 | 2014 | 5 | 0.110 |
Why?
|
| Cholecalciferol | 2 | 2024 | 8 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2014 | 27 | 0.110 |
Why?
|
| Skin | 1 | 2014 | 38 | 0.110 |
Why?
|
| Parathyroid Hormone | 1 | 2014 | 13 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 11 | 0.110 |
Why?
|
| Judgment | 1 | 2014 | 2 | 0.110 |
Why?
|
| Energy Metabolism | 2 | 2004 | 13 | 0.110 |
Why?
|
| Dietary Supplements | 2 | 2024 | 40 | 0.110 |
Why?
|
| Cultural Characteristics | 1 | 2013 | 15 | 0.110 |
Why?
|
| South America | 1 | 2013 | 27 | 0.110 |
Why?
|
| Body Fluid Compartments | 1 | 2013 | 2 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2024 | 272 | 0.100 |
Why?
|
| Growth | 1 | 2013 | 14 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2024 | 65 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2011 | 9 | 0.090 |
Why?
|
| Schools | 2 | 2024 | 73 | 0.090 |
Why?
|
| Bone Resorption | 2 | 2009 | 3 | 0.090 |
Why?
|
| Environment Design | 2 | 2024 | 3 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2023 | 107 | 0.090 |
Why?
|
| Hip Joint | 1 | 2011 | 3 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 22 | 0.090 |
Why?
|
| Calcifediol | 2 | 2024 | 6 | 0.090 |
Why?
|
| Contraceptive Agents, Female | 2 | 2009 | 47 | 0.090 |
Why?
|
| Reproductive Health | 1 | 2011 | 51 | 0.080 |
Why?
|
| African Americans | 1 | 2010 | 47 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 472 | 0.080 |
Why?
|
| Infrared Rays | 1 | 2009 | 1 | 0.080 |
Why?
|
| Head | 1 | 2009 | 8 | 0.080 |
Why?
|
| Glucose Tolerance Test | 2 | 2019 | 33 | 0.080 |
Why?
|
| Animals | 2 | 2022 | 1081 | 0.080 |
Why?
|
| Minnesota | 1 | 2007 | 2 | 0.070 |
Why?
|
| Maternal Behavior | 1 | 2007 | 3 | 0.070 |
Why?
|
| Housing | 1 | 2007 | 24 | 0.070 |
Why?
|
| Norethindrone | 1 | 2007 | 26 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2007 | 44 | 0.070 |
Why?
|
| Oligomenorrhea | 2 | 1998 | 2 | 0.070 |
Why?
|
| Amenorrhea | 2 | 1998 | 9 | 0.070 |
Why?
|
| Income | 2 | 2020 | 85 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2006 | 19 | 0.060 |
Why?
|
| Parity | 2 | 2016 | 19 | 0.060 |
Why?
|
| Reproductive Behavior | 1 | 2005 | 3 | 0.060 |
Why?
|
| Risk | 2 | 2019 | 87 | 0.060 |
Why?
|
| Calcium | 1 | 2005 | 49 | 0.060 |
Why?
|
| Calcium, Dietary | 1 | 2005 | 25 | 0.060 |
Why?
|
| Atlases as Topic | 1 | 2025 | 5 | 0.060 |
Why?
|
| Treponema | 1 | 2025 | 5 | 0.060 |
Why?
|
| Metagenomics | 1 | 2025 | 13 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2025 | 29 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2020 | 889 | 0.060 |
Why?
|
| Cameroon | 1 | 2024 | 9 | 0.060 |
Why?
|
| Pedestrians | 1 | 2024 | 1 | 0.060 |
Why?
|
| Logistic Models | 1 | 2005 | 254 | 0.060 |
Why?
|
| Collagen Type I | 2 | 2014 | 6 | 0.060 |
Why?
|
| Bone Remodeling | 1 | 2024 | 11 | 0.060 |
Why?
|
| Spirometry | 1 | 2024 | 12 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2024 | 40 | 0.050 |
Why?
|
| Iontophoresis | 2 | 2014 | 5 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2024 | 57 | 0.050 |
Why?
|
| Steroids | 1 | 2024 | 14 | 0.050 |
Why?
|
| Risk Reduction Behavior | 2 | 2014 | 39 | 0.050 |
Why?
|
| Vitamins | 1 | 2024 | 23 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2024 | 122 | 0.050 |
Why?
|
| Liver | 1 | 2024 | 74 | 0.050 |
Why?
|
| Bicycling | 1 | 2003 | 6 | 0.050 |
Why?
|
| India | 2 | 2014 | 62 | 0.050 |
Why?
|
| United Kingdom | 1 | 2023 | 33 | 0.050 |
Why?
|
| Uganda | 1 | 2023 | 197 | 0.050 |
Why?
|
| Tenofovir | 1 | 2024 | 171 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 244 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 13 | 0.050 |
Why?
|
| C-Peptide | 1 | 2022 | 13 | 0.050 |
Why?
|
| Sugars | 1 | 2022 | 14 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 25 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Anti-HIV Agents | 2 | 2024 | 1324 | 0.050 |
Why?
|
| Gastrointestinal Hormones | 1 | 2022 | 4 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor, Endocrine-Gland-Derived | 1 | 2022 | 4 | 0.050 |
Why?
|
| Sorting Nexins | 1 | 2022 | 4 | 0.050 |
Why?
|
| Ribonucleoproteins | 1 | 2022 | 6 | 0.050 |
Why?
|
| Histones | 1 | 2022 | 7 | 0.050 |
Why?
|
| Genome | 1 | 2022 | 9 | 0.050 |
Why?
|
| Autoantigens | 1 | 2022 | 10 | 0.050 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2021 | 7 | 0.050 |
Why?
|
| Anthropology, Cultural | 1 | 2021 | 5 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 6 | 0.040 |
Why?
|
| Scotland | 1 | 2021 | 5 | 0.040 |
Why?
|
| Switzerland | 1 | 2021 | 2 | 0.040 |
Why?
|
| Geography, Medical | 1 | 2021 | 3 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 11 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 11 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2020 | 15 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2017 | 799 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 50 | 0.040 |
Why?
|
| World Health Organization | 1 | 2021 | 137 | 0.040 |
Why?
|
| Reference Values | 2 | 2010 | 64 | 0.040 |
Why?
|
| Research | 1 | 2020 | 65 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 64 | 0.040 |
Why?
|
| Goals | 1 | 2019 | 7 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2019 | 8 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 124 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 32 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 32 | 0.040 |
Why?
|
| Quality of Life | 1 | 2021 | 177 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2019 | 1 | 0.040 |
Why?
|
| Metabolomics | 1 | 2019 | 5 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2019 | 24 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 89 | 0.040 |
Why?
|
| Apoptosis | 1 | 2019 | 40 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2018 | 16 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 188 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 152 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2017 | 15 | 0.030 |
Why?
|
| Play and Playthings | 1 | 2016 | 3 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 91 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2016 | 2 | 0.030 |
Why?
|
| Plethysmography | 1 | 2016 | 5 | 0.030 |
Why?
|
| Nutritional Requirements | 1 | 2016 | 6 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 279 | 0.030 |
Why?
|
| Sanitation | 1 | 2016 | 17 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 45 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Alkynes | 1 | 2015 | 117 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2015 | 123 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 171 | 0.030 |
Why?
|
| Peer Influence | 1 | 2015 | 4 | 0.030 |
Why?
|
| Lopinavir | 1 | 2015 | 137 | 0.030 |
Why?
|
| Social Norms | 1 | 2015 | 8 | 0.030 |
Why?
|
| Gait | 1 | 2015 | 2 | 0.030 |
Why?
|
| Pelvis | 1 | 2015 | 5 | 0.030 |
Why?
|
| Parent-Child Relations | 1 | 2015 | 16 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 154 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2015 | 15 | 0.030 |
Why?
|
| Parenting | 1 | 2015 | 22 | 0.030 |
Why?
|
| Diaphyses | 1 | 2014 | 2 | 0.030 |
Why?
|
| Growth Plate | 1 | 2014 | 3 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2014 | 1 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 253 | 0.030 |
Why?
|
| Skin Physiological Phenomena | 1 | 2014 | 5 | 0.030 |
Why?
|
| Vasodilation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2014 | 8 | 0.030 |
Why?
|
| Peptides | 1 | 2014 | 40 | 0.030 |
Why?
|
| Breast Feeding | 1 | 1995 | 120 | 0.030 |
Why?
|
| Homeostasis | 1 | 2014 | 9 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 127 | 0.030 |
Why?
|
| Community Health Services | 1 | 2014 | 58 | 0.030 |
Why?
|
| Rural Health Services | 1 | 2014 | 48 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2013 | 7 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 385 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2013 | 17 | 0.030 |
Why?
|
| Guatemala | 1 | 2013 | 8 | 0.030 |
Why?
|
| Philippines | 1 | 2013 | 10 | 0.030 |
Why?
|
| Brazil | 1 | 2013 | 47 | 0.030 |
Why?
|
| Educational Status | 1 | 2013 | 68 | 0.030 |
Why?
|
| ROC Curve | 1 | 2011 | 51 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 656 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2011 | 115 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2009 | 8 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2009 | 2 | 0.020 |
Why?
|
| Drug Implants | 1 | 2009 | 24 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 31 | 0.020 |
Why?
|
| Progestins | 1 | 2009 | 14 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 179 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 31 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2007 | 68 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 156 | 0.020 |
Why?
|
| New Zealand | 1 | 2007 | 8 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2007 | 125 | 0.020 |
Why?
|